Formycon AG: Clinical Trials

4 trials sponsored by Formycon AG, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated. 2 Phase 4, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 42Completed 2
Phase 11Completed 1
Phase 31Terminated 1

Follow Formycon AG: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)
FYB206, Keytruda - Non Small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer
Phase 3TerminatedFormycon AG252024-10-032025-06-26
Ocular Safety and Usability Study for FYB203 PFS
FYB203 2 mg (0.05 mL of 40 mg/mL) - Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema
Phase 4CompletedFormycon AG302024-09-202024-11-27
Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients
FYB206, Keytruda - Melanoma, Stage II, Melanoma Stage III
Phase 1CompletedFormycon AG962024-07-012026-10-20
Ocular Safety and Usability Study for FYB201 PFS
FYB201 0.5 mg (0.05 mL of 10 mg/mL) - Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema
Phase 4CompletedFormycon AG312024-06-112024-11-27

Conditions studied

Macular Degeneration (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Diabetic Retinopathy (1)  ·  Lung Neoplasms (1)  ·  Melanoma (1)

Interventions

pembrolizumab (2)

Countries

Georgia (2)  ·  United States (2)  ·  Bosnia and Herzegovina (1)  ·  Bulgaria (1)  ·  Estonia (1)  ·  Lithuania (1)  ·  Malaysia (1)  ·  Moldova (1)  ·  North Macedonia (1)  ·  Poland (1)  ·  Romania (1)  ·  Serbia (1)  ·  Turkey (Türkiye) (1)  ·  Ukraine (1)

NIH funding

2023 (2)